{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:44:06Z","timestamp":1781196246627,"version":"3.54.1"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,22]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>This study aimed to compare the effectiveness and safety of neuromuscular blockers, mesenchymal stem cells (MSC), and inhaled pulmonary vasodilators (IV) for acute respiratory distress syndrome through a network meta-analysis of randomized controlled trials (RCTs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We searched Chinese and English databases, including China National Knowledge Infrastructure, The Cochrane Library, PubMed, and EMbase, with no time restrictions. We conducted a network meta-analysis and reported the results according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. We included 27 clinical RCTs, all of which were two-arm trials, totaling 3492 patients. We selected 28-day mortality as the primary outcome measure, whereas 90-day mortality, ventilator-free days, and oxygenation served as secondary outcome measures for analysis and comparison.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We selected 3 treatment modalities and evaluated their clinical trials in comparison with the standard control group. For the 28-day in-hospital mortality, we included 21 RCTs, involving 2789 patients. Compared to standard treatment, neuromuscular blockers were associated with reduced 28-day hospital mortality (odds ratios [OR] 0.52, 95% confidence intervals [CI] (0.31, 0.88)), while IV and MSC were not associated with reduced hospital mortality (OR 0.89, 95% CI (0.50, 1.55); OR 0.90, 95% CI (0.49, 1.66)). In terms of 90-day mortality, days free of mechanical ventilation, and improvement in oxygenation, there were no significant differences compared to standard treatment with neuromuscular blockers, MSC, and IV.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Neuromuscular blockers significantly reduced the 28-day mortality rate in acute respiratory distress syndrome patients. However, in terms of 90-day mortality, ventilator-free days, oxygenation improvement, IV, MSC, and neuromuscular blockers did not significantly improve.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000040472","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T20:00:52Z","timestamp":1732564852000},"page":"e40472","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of several common drugs in the treatment of acute respiratory distress syndrome: A systematic review and network meta-analysis"],"prefix":"10.1097","volume":"103","author":[{"given":"Qing-Kuo","family":"Liu","sequence":"first","affiliation":[{"name":"Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Han","family":"Xiang","sequence":"additional","affiliation":[{"name":"Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yan","family":"Dong","sequence":"additional","affiliation":[{"name":"Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qi","family":"Wen","sequence":"additional","affiliation":[{"name":"Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4488-4840","authenticated-orcid":false,"given":"Hao","family":"Hao","sequence":"additional","affiliation":[{"name":"Intensive Care Unit, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","first-page":"2526","article-title":"Acute respiratory distress syndrome: the Berlin definition.","volume":"307","author":"Ranieri","year":"2012","journal-title":"JAMA"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2016.0291","article-title":"Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries.","volume":"315","author":"Bellani","year":"2016","journal-title":"JAMA"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/17476348.2020.1804365","article-title":"Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis.","volume":"14","author":"Hasan","year":"2020","journal-title":"Expert Rev Respir Med"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0140-6736(21)00439-6","article-title":"Acute respiratory distress syndrome.","volume":"398","author":"Meyer","year":"2021","journal-title":"Lancet"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00134-023-07050-7","article-title":"ESICM guidelines on acute respiratory distress syndrome: Definition, phenotyping and respiratory support strategies.","volume":"49","author":"Grasselli","year":"2023","journal-title":"Intensive Care Med"},{"key":"R6-20250503","first-page":"m3379","article-title":"A living WHO guideline on drugs for COVID-19.","volume":"370","author":"Lamontagne","year":"2020","journal-title":"BMJ"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1056\/NEJMoa2215145","article-title":"Hydrocortisone in severe communityacquired pneumonia.","volume":"388","author":"Dequin","year":"2023","journal-title":"N Engl J Med"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.hrtlng.2022.10.001","article-title":"The use of early neuromuscular blockage in acute respiratory distress syndrome: a systematic review and meta-analyses of randomized clinical trials.","volume":"57","author":"Savoie-White","year":"2023","journal-title":"Heart Lung"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40635-020-00348-6","article-title":"Neuromuscular blocking agents in acute respiratory distress syndrome: updated systematic review and meta-analysis of randomized trials.","volume":"8","author":"Tarazan","year":"2020","journal-title":"Intensive Care Med Exp"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4187\/respcare.07849","article-title":"Neuromuscular blocking agents for ARDS: a systematic review and meta-analysis.","volume":"66","author":"Torbic","year":"2021","journal-title":"Respir Care"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13054-022-04287-4","article-title":"The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials.","volume":"27","author":"Wang","year":"2023","journal-title":"Crit Care"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13287-022-02956-3","article-title":"Safety, efficacy and biomarkers analysis of mesenchymal stromal cells therapy in ARDS: A systematic review and meta-analysis based on phase I and II RCTs.","volume":"13","author":"Wang","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"e0931","DOI":"10.1097\/CCE.0000000000000931","article-title":"Inhaled prostacyclins for acute respiratory distress syndrome: a systematic review and meta-analysis.","volume":"5","author":"Torbic","year":"2023","journal-title":"Crit Care Explor"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/anae.13628","article-title":"The effect of inhaled nitric oxide in acute respiratory distress syndrome in children and adults: a cochrane systematic review with trial sequential analysis.","volume":"72","author":"Karam","year":"2017","journal-title":"Anaesthesia"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1177\/08850666221118271","article-title":"Inhaled pulmonary vasodilators in COVID-19 infection: a systematic review and meta-analysis.","volume":"37","author":"Khokher","year":"2022","journal-title":"J Intensive Care Med"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1007\/s001340101077","article-title":"A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome.","volume":"27","author":"Vincent","year":"2001","journal-title":"Intensive Care Med"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1164\/rccm.202201-0157OC","article-title":"A randomized trial of mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome from COVID-19.","volume":"207","author":"Bowdish","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s13287-023-03451-z","article-title":"Clinical efficacy and safety of multipotent adult progenitor cells (invimestrocel) for acute respiratory distress syndrome (ARDS) caused by pneumonia: a randomized, open-label, standard therapy-controlled, phase 2 multicenter study (ONE-BRIDGE).","volume":"14","author":"Ichikado","year":"2023","journal-title":"Stem Cell Res Ther"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1164\/rccm.2108121","article-title":"Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study.","volume":"167","author":"Gerlach","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-0040-1708557","article-title":"Early neuromuscular blockade in children with pediatric acute respiratory distress syndrome.","volume":"9","author":"Chandra","year":"2020","journal-title":"J Pediatr Intensive Care"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1056\/NEJMoa1901686","article-title":"Early neuromuscular blockade in the acute respiratory distress syndrome.","volume":"380","author":"Moss","year":"2019","journal-title":"N Engl J Med"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/01.CCM.0000104114.72614.BC","article-title":"Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome.","volume":"32","author":"Gainnier","year":"2004","journal-title":"Crit Care Med"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00134-016-4653-4","article-title":"Effects of neuromuscular blockers on transpulmonary pressures in moderate to severe acute respiratory distress syndrome.","volume":"43","author":"Guervilly","year":"2017","journal-title":"Intensive Care Med"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"1224865","DOI":"10.3389\/fmed.2023.1224865","article-title":"Efficacy of Wharton jelly mesenchymal stromal cells infusions in moderate to severe SARS-Cov-2 related acute respiratory distress syndrome: a phase 2a double-blind randomized controlled trial.","volume":"10","author":"Pochon","year":"2023","journal-title":"Front Med"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1164\/ajrccm.157.5.9707090","article-title":"Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study.","volume":"157","author":"Troncy","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa031154","article-title":"Inhaled nitric oxide in premature infants with the respiratory distress syndrome.","volume":"349","author":"Schreiber","year":"2003","journal-title":"N Engl J Med"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1080\/08035250600702594","article-title":"Inhaled nitric oxide in very preterm infants with severe respiratory distress syndrome.","volume":"95","author":"Dani","year":"2006","journal-title":"Acta Paediatr"},{"key":"R31-20250503","first-page":"58","article-title":"Inhaled prostacyclin improves oxygenation in patients with COVID-19-induced acute respiratory distress syndrome.","volume":"24","author":"Haeberle","year":"2023","journal-title":"medRxiv"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1001\/jama.291.13.1603","article-title":"Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial.","volume":"291","author":"Taylor","year":"2004","journal-title":"JAMA"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jpeds.2014.10.011","article-title":"Multicenter randomized controlled trial of inhaled nitric oxide for pediatric acute respiratory distress syndrome.","volume":"166","author":"Bronicki","year":"2015","journal-title":"J Pediatr"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1005372","article-title":"Neuromuscular blockers in early acute respiratory distress syndrome.","volume":"363","author":"Papazian","year":"2010","journal-title":"N Engl J Med"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1097\/01.CCM.0000239435.87433.0D","article-title":"Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome.","volume":"34","author":"Forel","year":"2006","journal-title":"Crit Care Med"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1513\/AnnalsATS.202004-374OC","article-title":"Randomized, placebo-controlled trial of inhaled treprostinil for patients at risk for acute respiratory distress syndrome.","volume":"18","author":"Ford","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00134-021-06570-4","article-title":"Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1\/2 trial.","volume":"48","author":"Bellingan","year":"2022","journal-title":"Intensive Care Med"},{"key":"R38-20250503","first-page":"687","article-title":"Specific clinical and immunological changes following mesenchymal stem cell transplantation in COVID-19\u2013induced acute respiratory distress syndrome patients: a phase-I clinical trial.","volume":"21","author":"Farkhad","year":"2022","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"R39-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1465-9921-15-39","article-title":"Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study.","volume":"15","author":"Zheng","year":"2014","journal-title":"Respir Res"},{"key":"R40-20250503","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13054-022-03930-4","article-title":"Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.","volume":"26","author":"Monsel","year":"2022","journal-title":"Crit Care"},{"key":"R41-20250503","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S2213-2600(18)30418-1","article-title":"Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial.","volume":"7","author":"Matthay","year":"2019","journal-title":"Lancet Respir Med"},{"key":"R42-20250503","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/sctm.20-0472","article-title":"Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1\/2a, randomized controlled trial.","volume":"10","author":"Lanzoni","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"R43-20250503","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4236\/ojanes.2013.32027","article-title":"Use of inhaled PGE1 to improve diastolic dysfunction, LVEDP, pulmonary hypertension and hypoxia in ARDS\u2014a randomised clinical trial.","volume":"03","author":"Siddiqui","year":"2013","journal-title":"Open J Anesthesiol"},{"key":"R44-20250503","first-page":"325","article-title":"Clinical study of early use of neuromuscular blocking agents in patients with severe sepsis and acute respiratory distress syndrome.","volume":"26","author":"Lyu","year":"2014","journal-title":"Zhonghua wei zhong bing ji jiu yi xue"},{"key":"R45-20250503","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00003246-199801000-00011","article-title":"Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial.","volume":"26","author":"Dellinger","year":"1998","journal-title":"Crit Care Med"},{"key":"R46-20250503","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM200005043421801","article-title":"Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.","volume":"342","author":"Brower","year":"2000","journal-title":"N Engl J Med"},{"key":"R47-20250503","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMsa1410639","article-title":"Driving pressure and survival in the acute respiratory distress syndrome.","volume":"372","author":"Amato","year":"2015","journal-title":"N Engl J Med"},{"key":"R48-20250503","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.3390\/jpm12091538","article-title":"Neuromuscular blockade in the pre- and COVID-19 ARDS patients.","volume":"12","author":"Tsolaki","year":"2022","journal-title":"J Pers Med"},{"key":"R49-20250503","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1378\/chest.109.4.1038","article-title":"The effects of neuromuscular paralysis on systemic and splanchnic oxygen utilization in mechanically ventilated patients.","volume":"109","author":"Marik","year":"1996","journal-title":"Chest"},{"key":"R50-20250503","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/ALN.0000000000000907","article-title":"Neuromuscular blocking agent cisatracurium attenuates lung injury by inhibition of nicotinic acetylcholine receptor-\u03b11.","volume":"124","author":"Fanelli","year":"2016","journal-title":"Anesthesiology"},{"key":"R51-20250503","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ccc.2021.05.009","article-title":"Pharmacologic treatments for acute respiratory distress syndrome.","volume":"37","author":"Qadir","year":"2021","journal-title":"Crit Care Clin"},{"key":"R52-20250503","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fimmu.2017.00339","article-title":"antimicrobial activity of mesenchymal stem cells: current status and new perspectives of antimicrobial peptide-based therapies.","volume":"8","author":"Alcayaga-Miranda","year":"2017","journal-title":"Front Immunol"},{"key":"R53-20250503","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1164\/rccm.201410-1765OC","article-title":"Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice.","volume":"192","author":"Monsel","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"R54-20250503","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13287-017-0662-7","article-title":"Mesenchymal stem cells microvesicles stabilize endothelial barrier function partly mediated by hepatocyte growth factor (HGF).","volume":"8","author":"Wang","year":"2017","journal-title":"Stem Cell Res Ther"},{"key":"R55-20250503","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/s41577-022-00763-8","article-title":"The roles of extracellular vesicles in the immune system.","volume":"23","author":"Buzas","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"R56-20250503","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1164\/rccm.201701-0170OC","article-title":"Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer.","volume":"196","author":"Morrison","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"R57-20250503","doi-asserted-by":"crossref","first-page":"154936","DOI":"10.1016\/j.cyto.2019.154936","article-title":"IL-27 is elevated in sepsis with acute hepatic injury and promotes hepatic damage and inflammation in the CLP model.","volume":"127","author":"Fan","year":"2020","journal-title":"Cytokine"},{"key":"R58-20250503","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s10875-013-9923-0","article-title":"IL-27 is elevated in acute lung injury and mediates inflammation.","volume":"33","author":"Xu","year":"2013","journal-title":"J Clin Immunol"},{"key":"R59-20250503","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41420-021-00785-6","article-title":"Exosomes from adipose-derived mesenchymal stem cells alleviate sepsis-induced lung injury in mice by inhibiting the secretion of IL-27 in macrophages.","volume":"8","author":"Wang","year":"2022","journal-title":"Cell Death Discov"},{"key":"R60-20250503","doi-asserted-by":"crossref","first-page":"102655","DOI":"10.1016\/j.redox.2023.102655","article-title":"miR-125b-5p in adipose derived stem cells exosome alleviates pulmonary microvascular endothelial cells ferroptosis via Keap1\/Nrf2\/GPX4 in sepsis lung injury.","volume":"62","author":"Shen","year":"2023","journal-title":"Redox Biol"},{"key":"R61-20250503","doi-asserted-by":"crossref","first-page":"9973457","DOI":"10.1155\/2021\/9973457","article-title":"BMSC-derived exosomes ameliorate LPS-induced acute lung injury by miR-384-5p-controlled alveolar macrophage autophagy.","volume":"2021","author":"Liu","year":"2021","journal-title":"Oxid Med Cell Longev"},{"key":"R62-20250503","first-page":"112","article-title":"The pulmonary vascular lesions of the adult respiratory distress syndrome.","volume":"112","author":"Tomashefski","year":"1983","journal-title":"Am J Pathol"},{"key":"R63-20250503","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/bph.14512","article-title":"Inhaled nitric oxide.","volume":"176","author":"Yu","year":"2019","journal-title":"Br J Pharmacol"},{"key":"R64-20250503","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/17476348.2017.1317599","article-title":"The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.","volume":"11","author":"Del Pozo","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"R65-20250503","first-page":"1766","article-title":"Acute respiratory distress syndrome and the use of inhaled pulmonary vasodilators in the COVID-19 era: a narrative review.","volume":"12","author":"Nasrullah","year":"2022","journal-title":"Life (Basel)"},{"key":"R66-20250503","article-title":"Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults.","volume":"2016","author":"Gebistorf","year":"2016","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040472","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:35:11Z","timestamp":1746318911000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":66,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040472","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]}}}